MIST Stock Price, Milestone Pharmaceuticals Quote, Chart

Market Summary

USD1.73-0.02

Delayed

-1.14%

MIST Stock Price

View Fullscreen

MIST RSI Chart

MIST Valuation

Market Cap

92.1M

Price/Earnings (Trailing)

-1.67

Price/Sales (Trailing)

92.14

EV/EBITDA

-2.36

Price/Free Cashflow

-2.22

MIST Price/Sales (Trailing)

MIST Profitability

EBT Margin

-5968.50%

Return on Equity

-138%

Return on Assets

-57.38%

Free Cashflow Yield

-45.11%

MIST Fundamentals

MIST Revenue

Revenue (TTM)

1.0M

Rev. Growth (Yr)

-100%

MIST Earnings

Earnings (TTM)

-55.1M

Earnings Growth (Yr)

30.74%

Earnings Growth (Qtr)

23.93%

Breaking Down MIST Revenue

Last 7 days

1.8%

Last 30 days

-1.1%

Last 90 days

13.1%

Trailing 12 Months

-57.9%

How does MIST drawdown profile look like?

MIST Financial Health

Current Ratio

22.75

Debt/Equity

1.27

Debt/Cashflow

-0.82

MIST Investor Care

Shares Dilution (1Y)

59.66%

Diluted EPS (TTM)

-1.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	5.5M	6.0M	4.5M	1.0M
2022	11.7M	0	8.3M	5.0M
2021	4.3M	7.9M	11.4M	15.0M
2020	2.5M	2.0M	1.2M	726.0K
2019	1.2M	1.7M	2.1M	2.6M
2018	0	0	0	711.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Milestone Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 22, 2023	rtw investments, lp	sold	-	-	-1,059,000	-
Dec 05, 2022	bharucha david	bought	32,830	4.69	7,000	chief medical officer
Dec 01, 2022	bharucha david	bought	14,580	4.86	3,000	chief medical officer
Oct 21, 2022	liebert debra k.	bought	21,040	5.26	4,000	-
Oct 20, 2022	pasternak richard c	bought	52,000	5.2	10,000	-
Oct 20, 2022	liebert debra k.	bought	52,900	5.29	10,000	-
Oct 19, 2022	wills robert james	bought	73,950	4.93	15,000	-
Oct 19, 2022	tomsicek michael john	bought	79,800	5.32	15,000	-
Sep 14, 2022	liebert debra k.	acquired	-	-	127	-
Sep 07, 2022	rtw investments, lp	bought	13,564,500	8.71	1,557,350	-

Which funds bought or sold MIST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Ancora Advisors LLC	added	20.00	23,900	107,400	-%
May 15, 2024	CITADEL ADVISORS LLC	added	867	3,675,310	4,067,600	-%
May 15, 2024	Altium Capital Management LP	new	-	2,171,060	2,171,060	0.86%
May 15, 2024	GOLDMAN SACHS GROUP INC	unchanged	-	162,368	2,421,990	-%
May 15, 2024	ORBIMED ADVISORS LLC	new	-	3,580,000	3,580,000	0.07%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	91.08	2,615,750	5,111,540	-%
May 15, 2024	Stonepine Capital Management, LLC	new	-	2,617,510	2,617,510	2.08%
May 15, 2024	Boxer Capital, LLC	unchanged	-	37,081	553,123	0.03%
May 15, 2024	Nantahala Capital Management, LLC	new	-	3,132,500	3,132,500	0.18%
May 15, 2024	RTW INVESTMENTS, LP	unchanged	-	390,733	5,828,420	0.09%

Are Funds Buying or Selling MIST?

Are funds buying MIST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MIST

No. of Funds

Unveiling Milestone Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	2.8%	925,048	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.99%	3,354,825	SC 13G/A
Feb 09, 2024	goldman sachs group inc	4.1%	1,359,540	SC 13G/A
Jan 29, 2024	integrated core strategies (us) llc	5.2%	1,727,245	SC 13G/A
Jan 24, 2024	blackrock inc.	9.8%	3,270,749	SC 13G/A
Nov 09, 2023	alta fundamental advisers llc	5.0%	1,671,289	SC 13D
Feb 14, 2023	ra capital management, l.p.	0%	0	SC 13G/A
Feb 14, 2023	orbimed capital llc	0%	0	SC 13G/A
Feb 14, 2023	boxer capital, llc	2.0%	698,861	SC 13G/A
Feb 14, 2023	venrock healthcare capital partners iii, l.p.	6.4%	2,208,812	SC 13G/A

Recent SEC filings of Milestone Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
Apr 29, 2024	10-K/A	Annual Report
Apr 08, 2024	8-K	Current Report
Mar 28, 2024	8-K	Current Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 04, 2024	8-K	Current Report
Mar 01, 2024	424B5	Prospectus Filed
Feb 28, 2024	424B5	Prospectus Filed

Peers (Alternatives to Milestone Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Milestone Pharmaceuticals Inc News

Latest updates

Milestone Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-	-	-	-	-	1,000,000	3,500,000	1,500,000	750,000	-	-	15,000,000	7,548,000	96,000	89,000	126,000	415,000	603,000	821,000	672,000	500,000	292,500
S&GA Expenses	-100.0%	-	3,371,000	4,227,000	4,445,000	3,889,000	4,123,000	4,034,000	3,643,000	3,787,000	2,961,000	3,018,000	2,633,000	1,674,000	2,952,000	2,956,000	2,703,000	2,279,500	2,104,000	1,641,000	979,000	1,217,500
R&D Expenses	-33.3%	3,639,000	5,452,000	6,721,000	8,622,000	10,257,000	10,578,000	9,826,000	8,768,000	10,916,000	9,733,000	9,427,000	8,595,000	5,766,000	8,228,000	8,622,000	11,872,000	14,148,500	9,545,000	10,527,000	7,765,000	7,296,500
EBITDA Margin	1.5%	-56.19	-57.04	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	1.6%	872,000	858,500	841,000	820,000	33,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-17,000	-	-	-1,000	-73,000	-4,000	22,000	56,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-16,884,000	-14,225,000	-	-	-8,666,000	-11,996,000	-12,979,000	-16,343,000	-18,289,000	-12,904,000	-13,662,000	-10,430,000	-9,660,000
EBT Margin	0%	-59.68	-59.68	-12.98	-9.73	-10.62	-11.68	-6.21	-4.44	-3.45	-4.19	-6.36	-11.64	-	-	-	-	-	-	-	-	-
Net Income	23.9%	-10,354,000	-13,611,000	-15,081,000	-16,043,000	-14,950,000	-13,177,000	-14,556,000	-14,007,000	-16,884,000	-14,225,000	770,000	-12,514,000	-8,666,000	-11,979,000	-12,979,000	-16,343,000	-18,288,000	-12,831,000	-13,658,000	-10,452,000	-9,716,000
Net Income Margin	7.7%	-55.09	-59.68	-13.17	-9.79	-10.79	-11.68	-7.45	-3.80	-2.86	-3.03	-4.12	-10.74	-	-	-	-	-	-	-	-	-
Free Cashflow	8.8%	-8,965,000	-9,827,000	-12,178,000	-10,595,000	-13,936,000	-12,972,000	-11,676,000	-14,050,000	-12,478,000	-9,493,000	914,000	-12,571,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	27.6%	96.00	75.00	87.00	97.00	111	74.00	86.00	91.00	106	120	134	145	138	150	109	93.00	105	123	142	152	78.00
Current Assets	28.7%	94.00	73.00	85.00	95.00	109	72.00	83.00	91.00	105	119	133	144	137	149	107	92.00	104	122	141	152	77.00
Cash Equivalents	-26.4%	10.00	14.00	10.00	33.00	74.00	8.00	37.00	63.00	92.00	114	111	98.00	72.00	72.00	47.00	53.00	102	120	107	111	71.00
Net PPE	-10.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-4.1%	56.00	58.00	59.00	57.00	57.00	8.00	9.00	5.00	5.00	7.00	6.00	6.00	6.00	7.00	7.00	5.00	6.00	9.00	9.00	7.00	4.00
Current Liabilities	-42.8%	4.00	7.00	8.00	7.00	8.00	6.00	7.00	4.00	5.00	7.00	6.00	5.00	6.00	6.00	6.00	5.00	5.00	8.00	9.00	6.00	4.00
Long Term Debt	1.8%	51.00	50.00	49.00	48.00	47.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	138.0%	40.00	17.00	29.00	40.00	54.00	66.00	77.00	87.00	101	113	127	140	132	143	102	88.00	100	115	133	145	73.00
Retained Earnings	-3.2%	-336	-326	-312	-297	-281	-266	-251	-237	-220	-207	-189	-175	-175	-163	-154	-142	-129	-113	-95.21	-82.38	-68.72
Additional Paid-In Capital	4.5%	35.00	34.00	32.00	29.00	27.00	24.00	22.00	20.00	18.00	16.00	14.00	12.00	10.00	9.00	7.00	6.00	5.00	4.00	3.00	3.00	3.00
Shares Outstanding	58.7%	53.00	33.00	33.00	33.00	33.00	34.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	96.00	-	-	-	185	-	-	-	164	-	-	-	93.00	-	-	-	218	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	8.8%	-8,934	-9,796	-12,160	-10,564	-13,904	-12,862	-11,573	-14,085	-13,949	-12,377	-9,392	1,015	-12,470	-8,757	-7,334	-16,562	-18,079	-16,603	-8,298	-11,518	-14,733
Share Based Compensation	-19.4%	1,512	1,877	2,872	2,492	2,293	2,143	2,380	2,411	2,114	1,975	2,024	1,912	1,368	1,430	1,343	1,191	981	354	350	276	211
Cashflow From Investing	-297.5%	-27,014	13,676	-10,857	-28,031	29,968	-17,015	-17,050	-15,059	-8,000	15,000	23,000	20,000	12,000	-14,000	-24,000	-	-	29,899	4,706	-	-
Cashflow From Financing	3231800.0%	32,319	1.00	305	-2,767	50,253	227	2,672	140	49.00	92.00	24.00	4,920	19.00	48,157	24,818	172	77.00	21.00	-731	86,092	25.00
Buy Backs	-	-	-	-	-	14,115	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MIST Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 10,131	$ 13,760
Short-term investments	79,350	52,243
Research and development tax credits receivable	711	643
Prepaid expenses	2,362	3,178
Other receivables	1,413	3,208
Total current assets	93,967	73,032
Operating lease right-of-use assets	1,785	1,917
Property and equipment	249	277
Total assets	96,001	75,226
Current liabilities
Accounts payable and accrued liabilities	3,575	6,680
Operating lease liabilities	555	546
Total current liabilities	4,130	7,226
Operating lease liabilities, net of current portion	1,306	1,457
Senior secured convertible notes	50,644	49,772
Total liabilities	56,080	58,455
Shareholders' Equity
Common shares, no par value, unlimited shares authorized 33,483,111 shares issued and outstanding as of December 31, 2023, 34,286,002 shares issued and outstanding as of December 31, 2022	287,879	260,504
Pre-funded warrants - 9,577,257 issued and outstanding as of December 31, 2023 and 8,518,257 as of December 31, 2022	53,076	48,459
Additional paid-in capital	35,346	33,834
Accumulated deficit	(336,380)	(326,026)
Total shareholders' equity	39,921	16,771
Total liabilities and shareholders' equity	$ 96,001	$ 75,226

About Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in MontrÃƒÂ©al, Canada.

CEO	Mr. Joseph G. Oliveto M.B.A.
WEBSITE	milestonepharma.com
INDUSTRY	Biotechnology
EMPLOYEES	39

Milestone Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Milestone Pharmaceuticals Inc? What does MIST stand for in stocks?

MIST is the stock ticker symbol of Milestone Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Milestone Pharmaceuticals Inc (MIST)?

As of Fri May 17 2024, market cap of Milestone Pharmaceuticals Inc is 92.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MIST stock?

You can check MIST's fair value in chart for subscribers.

What is the fair value of MIST stock?

You can check MIST's fair value in chart for subscribers. The fair value of Milestone Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Milestone Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MIST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Milestone Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MIST is over valued or under valued. Whether Milestone Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Milestone Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MIST.

What is Milestone Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MIST's PE ratio (Price to Earnings) is -1.67 and Price to Sales (PS) ratio is 92.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MIST PE ratio will change depending on the future growth rate expectations of investors.